banner
 
bar

program

slides
bar
 
 

Advanced and Metastatic Breast Cancer

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 20, 2012 through July 20, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all seven segments totaling 2 hours and 5 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in metastatic breast cancer.

Release Date

July 20, 2012

Expiration Date

July 20, 2014

Intended Audience

This program is intended for all oncologists, surgical oncologists, breast cancer specialists, radiologists, hematologists, and other healthcare providers caring for patients with breast cancer.

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoThis CME activity is supported
by an educational grant
from Eisai, Inc.

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

EDITH A. PEREZ, MD
(Program Chairperson)

Serene M. and Frances C. Durling Professor of Medicine
Deputy Director at Large, Mayo Clinic Cancer Center
Group Vice Chair, Alliance for Clinical Trials in Oncology
Mayo Clinic
Jacksonville, FL

Grant/Research Support: Sanofi Oncology, Genentech, GSK


HOWARD A. BURRIS, III, MD, FACP
Chief Medical Officer
Executive Director of Drug Development
Sarah Cannon Research Institute
Nashville, TN

Nothing to disclose


SUSAN MOOBERRY, PhD
Professor
Departments of Pharmacology, Medicine
Co-leader, Experimental and Developmental Therapeutics Program
Cancer Therapy and Research Center
University of Texas Health Science Center at San Antonio
San Antonio, TX

Consultant: Eisai Eribulin Preclinical Advisory Board
Grant/Research Support: Phoenix Biotechnology



DEBU TRIPATHY, MD
Professor of Medicine
University of Southern California
Los Angeles, CA

Nothing to disclose

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should:

  • Apply evidence-based strategies that may prolong survival in patients with metastatic breast cancer (MBC) who have received multiple, established chemotherapeutic treatment courses (i.e., heavily treated) with documented remissions
  • Detail the safety, efficacy, and survival prolongation profiles associated with novel treatments being evaluated for MSB, including the role of nontaxane, microtubule dynamics inhibitors
  • Review the tolerability factors, outcomes, and evidence-based rationale for the use of microtubule inhibitors in heavily pretreated women with metastatic breast cancer who had already received treatment with anthracycline and a taxane for MBC
  • Discuss rationale, combination therapy, trial design, and outcome metrics focused on progression-free survival and overall survival in heavily treated patients with MBC
  • Compare the tolerability, safety, and impact on clinical outcomes of late stage agents for MBC, focusing on comparative value of taxanes versus novel agents (microtubule inhibitors) when used as combination therapy with anthracyclines and similar settings

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

Anaphase
Antimitotic
Antitubulin
Baseline Characteristics
Bevacizumab
bisphosphonate
Breast Cancer
Palliation
CA163-048
Capecitabine
Centromere
chemotherapy
combination
cyclophosphamide
Denosumab
Docetaxel

Doxorubicin 6
Endocrine
Enhancers Induce Microtubule Bundles
Epothilones
Eribulin
Eribulin Mesylate
Everolimus
FAC
Gemcitabine
Halichondrin B
Hematotoxicity
Interphase
ixabepilone
ligand inhibitors

MDR
melphalan
Metaphase
Metastatic
Microtubule
mitomycin/5-FU
NCCN
agen
No Drug
Olaparib
paclitaxel
PARP Inhibitors
Pegylated lip. doxuribcin
physician's choice (Twelves, 2010 ASCO abstract)

Progression-free Survival
Bevacizumab
RANK
resistant HER2-pos disease
Taxane
Taxol
temozolomide
Trastuzumab
Tubulin Dimer
Tumor
Veliparib
Vinorelbine
zolendronic acid